EVAX

Evaxion Biotech A/S ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website evaxion-biotech.com
Employees(FY) 63
ISIN US29970R2040

Performance

-22.69%

-41.02%

-70.79%

-65.54%

-86.58%

YTD

-86.17%

Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

Advanced Technical Analysis

Technical Analysis of EVAX 2024-12-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 60 suggests a bullish outlook. However, the overall Technical Score of 35 reinforces a predominantly bearish sentiment, indicating that despite some bullish signals from oscillators, the prevailing trend remains negative.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EVAX

Stock Rank

Recent News & Updates

2024-12-16 19:00
Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity(Globenewswire)
2024-12-11 19:00
Evaxion establishes new AI-derived precision cancer vaccine concept(Globenewswire)
2024-12-08 19:00
Evaxion announces 2025 milestones reflecting continued strong strategy execution(Globenewswire)
2024-12-01 19:00
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress(Globenewswire)
2024-11-12 19:00
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing(Globenewswire)
2024-11-11 19:00
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1(Globenewswire)
2024-10-30 20:00
Evaxion announces business update and third quarter 2024 financial results(Globenewswire)
2024-10-27 20:00
Evaxion to announce business update and third quarter 2024 financial results on October 31(Globenewswire)
2024-10-08 20:00
Strong validation of Evaxion's AI-Immunology platform in multiple clinical trials(Globenewswire)
2024-10-03 19:27
Evaxion Biotech Charts Future with Innovative Immune Therapies(Yahoo Finance)
2024-10-02 20:00
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology platform(Globenewswire)
2024-09-25 19:30
Evaxion significantly expands vaccine development collaboration with MSD(Globenewswire)
2024-09-19 20:35
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing(Yahoo Finance)
2024-09-18 20:00
Evaxion launches improved AI-Immunology platform for vaccine antigen prediction(Globenewswire)
2024-09-16 00:07
Life Sciences Virtual Investor Forum Agenda Announced for September 19th(Yahoo Finance)
2024-09-15 19:00
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01(Globenewswire)
2024-09-08 20:00
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01(Globenewswire)
2024-09-08 19:00
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2(Globenewswire)
2024-08-13 19:00
Evaxion Announces Business Update and Second Quarter 2024 Financial Results(Globenewswire)
2024-08-11 19:27
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14(Globenewswire)
2024-08-07 20:00
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September(Globenewswire)
2024-07-15 19:30
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology at Computational Biology Conference(Globenewswire)
2024-07-02 20:05
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update(Globenewswire)
2024-06-25 19:30
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method(Globenewswire)
2024-06-16 20:44
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal(Globenewswire)
2024-06-12 21:55
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now(Zacks)
2024-06-02 20:00
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024(Globenewswire)
2024-05-28 02:52
EVAX Stock Earnings: Evaxion Biotech Beats EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-27 20:21
Evaxion Announces Business Update and First Quarter 2024 Financial Results(Globenewswire)
2024-05-23 05:00
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.